<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-122151</identifier>
<setSpec>1138-3593</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Bisphosphonate-related osteonecrosis of the jaw</dc:title>
<dc:description xml:lang="en">The bisphosphonates are stable inorganic pyrophosphate analogs that have demonstrated their efficacy in treatment of osteolytic lesions associated with bony metastases, and multiple myeloma, malignant hypercalcemia, Paget&#146;s disease, and osteoporosis. Several publications within the last few years have suggested that osteonecrosis of the jaw is associated with bisphosphonate therapy. The diagnosis and management strategies of the patients with bisphosphonate-related osteonecrosis of the jaw is very difficult. It is important for patients to be informed of the risk of this complication, so that they have the opportunity to assess the need for dental treatment before starting therapy. Preventive measures must be taken before during, and after treatment with bisphosphonates. If osteonecrosis of the jaw is present, management should be conservative: oral chlorhexidine and antibiotics. Surgical treatment should be reserved for those patients who are symptomatic (AU)</dc:description>
<dc:creator>Atanes-Sandoval, A. D</dc:creator>
<dc:creator>Atanes-Bonome, P</dc:creator>
<dc:creator>Atanes-Bonome, A</dc:creator>
<dc:creator>Ríos-Lage, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los bifosfonatos, análogos estables de los pirofosfatos inorgánicos, han demostrado su eficacia para el tratamiento de las lesiones osteolíticas asociadas a metástasis óseas o al mieloma múltiple, la hipercalcemia maligna, la enfermedad de Paget y la osteoporosis. Numerosas publicaciones durante los últimos a&#152;nos consideran que la osteonecrosis de los maxilares está asociada al tratamiento con bifosfonatos. El manejo diagnóstico y terapéutico de los pacientes con osteonecrosis de los maxilares es de una enorme dificultad. Es importante que los pacientes sean informados del riesgo de presentar esta complicación para tener la oportunidad de recibir procedimientos dentales previos al inicio del tratamiento. Las medidas preventivas deben realizarse antes, durante y después del tratamiento con bifosfonatos. Ante una osteonecrosis de los maxilares establecida, la actitud debe ser conservadora: enjuagues con clorhexidina y antibióticos. El tratamiento quirúrgico debe reservarse para aquellos pacientes que presenten síntomas (AU)</dc:description>
<dc:source>SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.);40(3): 143-148, abr. 2014. tab</dc:source>
<dc:identifier>ibc-122151</dc:identifier>
<dc:title xml:lang="es">Osteonecrosis de los maxilares relacionada con el tratamiento con bifosfonatos</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d10205^s22057</dc:subject>
<dc:subject>^d10177^s22057</dc:subject>
<dc:subject>^d4220^s22020</dc:subject>
<dc:subject>^d9562^s22057</dc:subject>
<dc:subject>^d^s22080</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:type>article</dc:type>
<dc:date>201404</dc:date>
</metadata>
</record>
</ibecs-document>
